Literature DB >> 24701475

Apo B/Apo A-I Ratio is Statistically A Better Predictor of Cardiovascular Disease (CVD) than Conventional Lipid Profile: A Study from Kathmandu Valley, Nepal.

Hem Kumar Tamang1, Uddhav Timilsina2, Khelanand Prasad Singh3, Sanjit Shrestha4, Ramendra Kumar Raman5, Pujan Panta6, Preeti Karna6, Laxmi Khadka6, Chandika Dahal7.   

Abstract

BACKGROUND: Apo B and Apo A-I, are structural and functional components of lipoprotein particles that serve as transporters of cholesterol. The apo B/apo A-I ratio reflects the cholesterol transport and has been shown to be strongly related to risk of Myocardial infarction, stroke and other Cardiovascular manifestations.
MATERIALS AND METHODS: Forty five participants with Cardiovascular Disease (CVD) and forty four healthy participants were included from different locations of Kathmandu valley, Nepal. Fasting blood samples were collected from ante-cubital vein and serum samples were used for lipid parameters, apo B and apo A-I levels measurement.
RESULTS: Statistically significant differences were found for apo B/apo A-I ratio, HDL-c and apo B between the groups. The other lipid parameters and lipid ratios such as total cholesterol, triglyceride, low density lipoprotein, TC/HDL-c, TG/HDL-c and LDL-c/HDL-c were not found to be significant.
CONCLUSION: Apo B/apo A-I ratio seems to have better predictive value than that of classical lipid parameters in cardiovascular risk assessment.

Entities:  

Keywords:  Apo B/apo A-I ratio; Cardiovascular disease; Lipid parameters; Predictive value

Year:  2014        PMID: 24701475      PMCID: PMC3972591          DOI: 10.7860/JCDR/2014/7588.4000

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  26 in total

1.  MDGs: chronic diseases are not on the agenda.

Authors:  Valentin Fuster; Janet Voûte
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

Review 2.  Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels.

Authors:  S Marcovina; C J Packard
Journal:  J Intern Med       Date:  2006-05       Impact factor: 8.989

3.  Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study.

Authors:  Christa Meisinger; Hannelore Loewel; Wilfried Mraz; Wolfgang Koenig
Journal:  Eur Heart J       Date:  2004-11-30       Impact factor: 29.983

4.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.

Authors:  G Walldius; I Jungner; I Holme; A H Aastveit; W Kolar; E Steiner
Journal:  Lancet       Date:  2001-12-15       Impact factor: 79.321

5.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

6.  Apo-B/AI ratio identifies cardiovascular risk in childhood: the Australian Aboriginal Birth Cohort study.

Authors:  Elizabeth A C Sellers; Gurmeet R Singh; Susan M Sayers
Journal:  Diab Vasc Dis Res       Date:  2009-04       Impact factor: 3.291

7.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

8.  Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population.

Authors:  Hyung-Kwan Kim; Sung-A Chang; Eue-Keun Choi; Yong-Jin Kim; Hyo-Soo Kim; Dae-Won Sohn; Byung-Hee Oh; Myoung-Mook Lee; Young-Bae Park; Yun-Shik Choi
Journal:  Int J Cardiol       Date:  2005-06-08       Impact factor: 4.164

9.  Epidemiology of coronary heart disease: the Framingham study.

Authors:  W P Castelli
Journal:  Am J Med       Date:  1984-02-27       Impact factor: 4.965

10.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.

Authors:  P J Barter; C M Ballantyne; R Carmena; M Castro Cabezas; M John Chapman; P Couture; J de Graaf; P N Durrington; O Faergeman; J Frohlich; C D Furberg; C Gagne; S M Haffner; S E Humphries; I Jungner; R M Krauss; P Kwiterovich; S Marcovina; C J Packard; T A Pearson; K Srinath Reddy; R Rosenson; N Sarrafzadegan; A D Sniderman; A F Stalenhoef; E Stein; P J Talmud; A M Tonkin; G Walldius; K M S Williams
Journal:  J Intern Med       Date:  2006-03       Impact factor: 8.989

View more
  9 in total

1.  Association of the SPT2 chromatin protein domain containing 1 gene rs17579600 polymorphism and serum lipid traits.

Authors:  Tao Guo; Rui-Xing Yin; Yuan Bin; Rong-Jun Nie; Xia Chen; Shang-Ling Pan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice.

Authors:  Oelfah Patel; Christo J F Muller; Elizabeth Joubert; Bernd Rosenkranz; Johan Louw; Charles Awortwe
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

3.  The SRGAP2 SNPs, their haplotypes and G × E interactions on serum lipid traits.

Authors:  Liu Miao; Rui-Xing Yin; Jin-Zhen Wu; Shuo Yang; Wei-Xiong Lin; Shang-Ling Pan
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

4.  Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors.

Authors:  Rodolfo A Kolliker Frers; Vanesa Cosentino; Julia Tau; Eduardo M Kerzberg; Adriana Urdapilleta; Monica Chiocconi; Nora Kogan; Matilde Otero-Losada; Francisco Capani
Journal:  Front Immunol       Date:  2018-02-26       Impact factor: 7.561

5.  Effects of Acute Cocoa Supplementation on Postprandial Apolipoproteins, Lipoprotein Subclasses, and Inflammatory Biomarkers in Adults with Type 2 Diabetes after a High-Fat Meal.

Authors:  Dustin W Davis; Rickelle Tallent; James W Navalta; Anthony Salazar; Timothy J Lyons; Arpita Basu
Journal:  Nutrients       Date:  2020-06-27       Impact factor: 5.717

6.  The Transcription Profile Unveils the Cardioprotective Effect of Aspalathin against Lipid Toxicity in an In Vitro H9c2 Model.

Authors:  Rabia Johnson; Phiwayinkosi V Dludla; Christo J F Muller; Barbara Huisamen; M Faadiel Essop; Johan Louw
Journal:  Molecules       Date:  2017-01-31       Impact factor: 4.411

7.  The Effect of Untraditional Lipid Parameters in the Development of Coronary Artery Disease: Atherogenic Index of Plasma, Atherogenic Coefficient and Lipoprotein Combined Index.

Authors:  Ersin Çelik; Ahmet Rıfkı Çora; Kadir Burhan Karadem
Journal:  J Saudi Heart Assoc       Date:  2021-09-20

8.  Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios.

Authors:  Mustapha Diaf; Boumediene M Khaled; Fériel Sellam
Journal:  Libyan J Med       Date:  2015-05-08       Impact factor: 1.743

9.  The apoB100/apoAI ratio is independently associated with the severity of coronary heart disease: a cross sectional study in patients undergoing coronary angiography.

Authors:  Yongyan Song; Yang Yang; Jingxiao Zhang; Yanmei Wang; Wenfeng He; Xiaoming Zhang; Jie Zhu; Zhan Lu
Journal:  Lipids Health Dis       Date:  2015-11-18       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.